

HEDGEYE



Health Care Position Monitor Update

TDOC + LVGO Merger, AMN Tracker, GH Claims, US Medical Economy

August 10, 2020



Hedgeye Health Care

Tom Tobin, Managing
Director, Health Care

Ttobin@Hedgeye.com

@HedgeyeHC

William McMahon, Analyst,
Health Care

Wmcmahon@Hedgeye.com

@HedgeyeMed

DISCLAIMER

Hedgeye Risk Management, LLC (“Hedgeye”) is a registered investment advisor, registered with the State of Connecticut. Hedgeye is not a broker dealer and does not provide investment advice to individuals. This research does not constitute an offer to sell, or a solicitation of an offer to buy any security or investment vehicle. This research is presented without regard for individual investment preferences or risk parameters; it is general information and does not constitute specific investment advice, nor does it constitute or contain any legal or tax opinions. This presentation is based on information from sources believed to be reliable. Hedgeye is not responsible for errors, inaccuracies or omissions of information. The opinions and conclusions contained in this report are those of the individual expressing those opinions or conclusion and are intended solely for the use of Hedgeye’s clients and subscribers, and the authorized recipients of the content. In reaching its own opinions and conclusions, Hedgeye and its employees have relied upon research conducted by Hedgeye’s employees, which is based upon sources considered credible and reliable within the industry. Neither Hedgeye, nor its employees nor any individual expressing opinions, conclusions or data are responsible for the validity or authenticity of the information upon which it has relied.

TERMS OF USE

This report is protected by United States and foreign copyright laws and is intended solely for the use of its authorized recipient. Access must be provided directly by Hedgeye. There is a fee associated with access to this report and the information and materials presented during the event. **Redistribution or republication of this report and its contents are strictly prohibited.** By joining this call or possessing these materials, you agree to these Terms. For more detail please refer to the appropriate sections of the Hedgeye Services Agreement and the Terms of Service at https://www.hedgeye.com/terms_of_service.

Health Care Position Monitor

For Week of August 10, 2020


Best Ideas - Longs						Best Ideas - Shorts					
LONG		Price	Mkt Cap (\$B)	Trend	Tail	SHORT		Price	Mkt Cap (\$B)	Trend	Tail
Active Longs						Active Shorts					
ONEM	1Life Healthcare, Inc.	\$ 30.00	\$3.8B	✓	✓	AMN	AMN Healthcare Services, Inc.	\$ 58.64	\$2.8B	×	×
TXG	10x Genomics Inc Class A	\$ 96.13	\$5.6B	✓	✓	EXAS	Exact Sciences Corporation	\$ 86.69	\$13.0B	×	×
TDOC	Teladoc Health, Inc.	\$ 193.72	\$15.7B	✓	✓						
Long Bias						Short Bias					
NTRA	Natera, Inc.	\$ 52.87	\$4.2B			HCA	HCA Healthcare Inc	\$ 130.27	\$44.0B		
						HRC	Hill-Rom Holdings, Inc.	\$ 95.13	\$6.3B		
						MASI	Masimo Corporation	\$ 217.08	\$11.9B		
						NVTA	Invitae Corp.	\$ 28.43	\$3.7B		
						ILMN	Illumina, Inc.	\$ 355.66	\$52.3B		
						GH	Guardant Health, Inc.	\$ 85.61	\$8.5B		

Disclaimer

Hedgeye’s “bias” represents Hedgeye’s outlook on companies currently under Hedgeye’s review, or for which timing is not right for greater coverage. Hedgeye may or may not provide further commentary on any or all companies represented on the bench and representation of a company on the bench does not forecast whether Hedgeye will or will not issue any additional material on that company.

GH | Claims Index v Reported Volume

Hedgeye: 14,392 tests versus 2Q20 Reported: 13,694 tests



GH | Claims Forecast v Earnings Result

Slight Deceleration in Clinical Volume, Bio-Pharma Business Cut in Half

Week	Q1-2017	Q2-2017	Q3-2017	Q4-2017	FY2017	Q1-2018	Q2-2018	Q3-2018	Q4-2018	FY2018	Q1-2019	Q2-2019	Q3-2019	Q4-2019	FY2019	Q1-2020	Q2-2020
1	36	94	64	103	297	94	79	97	64	333	142	127	148	241	658	35	189
2	70	82	70	103	324	130	124	88	103	445	88	157	142	108	496	103	97
3	42	112	106	79	339	88	100	73	82	342	112	88	133	149	482	148	171
4	73	94	100	64	330	145	118	97	106	466	76	118	176	131	500	168	162
5	91	70	70	76	306	82	103	100	115	400	97	173	103	153	525	159	139
6	48	79	127	103	357	88	112	85	76	360	100	109	125	163	496	215	144
7	67	79	100	97	342	115	97	67	94	372	127	109	122	216	574	177	124
8	88	91	91	51	321	79	100	79	88	345	88	97	183	144	512	201	165
9	85	91	85	103	363	79	58	118	82	336	109	136	116	148	509	133	134
10	127	100	61	121	409	51	58	85	85	279	97	121	165	123	506	157	124
11	91	82	85	97	354	121	79	73	79	351	127	94	113	152	487	155	-
12	91	106	115	94	406	97	106	82	173	457	109	164	126	175	573	203	-
13	112	106	97	42	357	82	154	100	127	463	115	154	148	223	641	167	-
Total	1,020	1,184	1,169	1,132	4,506	1,251	1,287	1,142	1,272	4,951	1,387	1,647	1,800	2,126	6,960	2,022	1,450

Correlation	
Claims Data & Reported Claims	98.2%

Forecast Q2-2020	
Reported Volume	
Clinical Test Volume	13,694

Hedgeye	
Method 1: Seasonal Wkly Distr.	15,225
Method 2: Avg Per Day x Total	14,551
Method 3: QTD Vol / Ratio Days	14,220
Method 4: Last Wkly Data Pt	13,742
Method 5: Avg Wkly Vol Carry	14,220
Average	14,392


- Our forecast focuses on Clinical Test Volume, which came in slightly below the low end of our forecast range.
- What you can not see here was the larger focus placed on the Biopharmaceutical Test Volume.
- 2Q20 Biopharma Volume of 2,807 tests decelerated nearly 47% on both a YoY and sequential basis.

Seasonal Weekly Distribution Pattern Based on Prior Years		Average Per Day QTD x Total Days		QTD Volume / Ratio of Completed Days		Last Weekly Data Point Carried Forward		Average Weekly Volume Carried Forward	
Week	Q2-2020	Week	Q2-2020	Week	Q2-2020	Week	Q2-2020	Week	Q2-2020
11	125	11	159	11	145	11	124	11	145
12	201	12	160	12	145	12	124	12	145
13	242	13	160	13	145	13	124	13	145
Total	2,018	Total	1,929	Total	1,885	Total	1,821	Total	1,885


*10 of 13 weeks completed in this data set.

ONEM | App Downloads


App Downloads, Daily



Active Users, Weekly



TDOC + LVGO Merger | Claims Data




Claims volume reflects the higher activity post COVID compared to app downloads, which are running below pre-COVID levels.



LVGO showing steady sequential pace of adoption in "disease management" claims.

AMN Tracker | July 2020

New Per Day, Weekly




New Per Day, Rolling 4 Week



Our Tracker accelerated sharply in the last 2 weeks, providing corroboration for management’s 2Q20 beat and positive outlook for 3Q20.


AMN | Valuation

		2020 Sales											
2020 EV/Sales		\$	2,185	\$	2,240	\$	2,300	\$	2,355	\$	2,415	\$	2,480
	1.0x		34.96		36.11		37.37		38.52		39.78		41.14
	1.1x		39.54		40.80		42.19		43.45		44.84		46.33
	1.2x		44.11		45.50		47.00		48.39		49.89		51.53
	1.3x		48.69		50.19		51.82		53.32		54.95		56.72
	1.4x		53.27		54.88		56.64		58.25		60.01		61.92
	1.5x		57.84		59.57		61.45		63.18		65.07		67.11
		2021 Sales											
2021 EV/Sales		\$	2,215	\$	2,285	\$	2,355	\$	2,425	\$	2,500	\$	2,580
	1.0x		35.59		37.05		38.52		39.99		41.56		43.23
	1.1x		40.23		41.84		43.45		45.07		46.79		48.64
	1.2x		44.87		46.63		48.39		50.14		52.03		54.04
	1.3x		49.51		51.41		53.32		55.22		57.27		59.44
	1.4x		54.14		56.20		58.25		60.30		62.50		64.85
	1.5x		58.78		60.98		63.18		65.38		67.74		70.25




The stock would seem to require a sustained positive revision to 2021 estimates to make a move higher from here.

AMN | Estimate Revisions




ADP Employment Report | July 2020

Health Care Employment YoY%




BLS | Health Care Employment

Health Care Labor Demand




BLS | Health Care Employment

Offices of Dentists




BLS | Health Care Employment

Offices of Physicians




BLS | Health Care Employment

Medical Laboratories




BLS | Health Care Employment

Hospitals



BLS | Health Care Employment

Diagnostic Imaging Centers



For more information, contact us at:

sales@hedgeye.com